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Comparison of Oral Prednisolone/Paracetamol and Oral
Indomethacin/Paracetamol Combination Therapy in the
Treatment of Acute Goutlike Arthritis: A Double-Blind,
Randomized, Controlled Trial
Chi Yin Man, MD
Ian T. F. Cheung, MD
Peter A. Cameron, MD
Timothy H. Rainer, MD
From the Accident and Emergency Medicine Academic Unit, The Chinese University of Hong Kong,
Hong Kong, China (Man, Cheung, Rainer); and Emergency and Trauma Centre, The Alfred Hospital,
Melbourne, Victoria, Australia (Cameron).
Study objective: We compare the analgesic efficacy and adverse effects of oral
prednisolone/acetaminophen and oral indomethacin/acetaminophen combination therapy in the
treatment of acute goutlike arthritis in patients presenting to an emergency department (ED).
Methods: This is a double-blind, randomized, controlled study in a university hospital emergency
department (ED) in the New Territories of Hong Kong. Patients older than 17 years and presenting
between February 1, 2003, and June 30, 2004, with a clinical diagnosis of goutlike arthritis were
randomized to receive either oral prednisolone/acetaminophen or oral indomethacin/acetaminophen
combination therapy. Primary outcome measures were pain scores, time to resolution of symptoms
and signs, and adverse effects. Secondary outcome measures were the need for additional
acetaminophen and relapse rate.
Results: There were 90 patients randomized: 46 patients to the indomethacin group and 44 patients
to the prednisolone group. Baseline characteristics, including pain scores, were similar in the 2
groups. Both treatment groups had a similar decrease in pain score in the ED. The mean rate of
decrease in pain score with activity for indomethacin was 1.71.6 (SD) mm per day and for
prednisolone was 2.92.0 (SD) mm per day (mean difference 1.2 mm/day; 95% confidence
interval 0.4 to 2.0 mm/day; P.0026). Although these differences were statistically significant, at no
time was the difference in mean pain score greater than 13 mm. Therefore, it is unclear whether
these differences are clinically significant. The mean total dose of acetaminophen consumed by the
prednisolone group was significantly more than in the indomethacin group (mean 10.3 g, range 1 to
21 g versus mean 6.4 g, range 1 to 21 g). Twenty-nine patients in the indomethacin group and 12
patients in the prednisolone group experienced adverse effects (P.05). The commonest adverse
effects in the indomethacin group were nausea, indigestion, epigastric pain, dizziness, and
gastrointestinal bleeding (N5; 11%). None of the patients in the prednisolone group developed
gastrointestinal bleeding. The relapse rate for both groups was similar.
Conclusion: In the treatment of acute goutlike arthritis, oral prednisolone/acetaminophen
combination is as effective as oral indomethacin/acetaminophen combination in relieving pain but is
associated with fewer adverse effects. [Ann Emerg Med. 2007;49:670-677.]
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INTRODUCTION
Background
Acute gouty arthritis is a crystal-induced inflammation of the
joint that primarily affects middle-aged and elderly adults. It is
the commonest cause of inflammatory joint disease in men
older than 40 years.1 It has been estimated that the overall
prevalence in the United Kingdom is 10 per 1,000, with men
affected more commonly than women.2 The diagnosis of acute
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gout is typically made clinically by the presence of rapid onset of
severe pain, swelling, and erythema of an affected joint and
definitively by demonstrating the presence of negatively
birefringent uric acid crystals in aspirated joint fluid. The
diagnosis is often made in the absence of joint aspiration
because this procedure is painful, poorly tolerated by some
patients, and declined by others and is sometimes difficult or
inconvenient to perform in a busy emergency department (ED).
The treatment of such patients is inconsistent, and evidence-
based guidelines to support clinical management are lacking.
Gout is an increasingly prevalent condition worldwide and
creates a heavy economic burden.1,3
Importance
Oral nonsteroidal antiinflammatory drugs (NSAIDs)
administered in high doses are recommended as first-line agents
in the management of gout but may be contraindicated because
of gastrointestinal hemorrhage or renal failure.4-12 Oral
colchicine may be as effective as NSAIDs but is limited by
toxicity at higher doses.13-15 Intraarticular corticosteroids may
also be administered for monoarticular disease and
intramuscular corticosteroids for podagra.4 A few small
controlled studies have compared oral NSAIDs with
intraarticular or intramuscular steroids and suggest that
NSAIDs are as effective as steroids in the treatment of acute
gout.16-18 However, NSAIDs have a significant rate of adverse
effects, including gastric irritation, gastrointestinal hemorrhage,
and renal failure.4 Although steroids cause severe adverse events
if taken at high doses for long periods, there appear to be few
adverse effects if they are taken in low to moderate doses for
short periods.19 The gastrointestinal adverse effects also appear
to be less severe than those of NSAIDs.5 Long-term effects, such
as osteoporosis and muscle wasting, are not relevant to acute
gout treatment. Oral NSAIDs have not been compared to oral
steroids in the management of acute gout.
Goals of This Investigation
The objective of this study was to compare the efficacy and
adverse effects of oral indomethacin/acetaminophen with oral
prednisolone/acetaminophen combination therapy in the
treatment of patients presenting to the ED with a clinical
diagnosis of acute goutlike arthritis.
MATERIALS AND METHODS
Study Design
In this prospective, randomized, double-blind, controlled
study, the analgesic efficacy and adverse effects of oral
prednisolone/acetaminophen and oral indomethacin/
acetaminophen combination were compared in patients
presenting to an ED with a clinical diagnosis of acute gouty
arthritis (Figure 1). Ethical approval was obtained from the local
institutional research ethics committee. Informed written
consent was obtained from each patient.
Setting
The ED of the Prince of Wales Hospital, a 1,400-bed
teaching hospital in the New Territories of Hong Kong, receives
about 160,000 new patients per annum, of whom about 25%
are admitted to the hospital. The hospital serves a population of
approximately 1.5 million. Gout is responsible for 1 to 2 patient
visits per day at Prince of Wales Hospital ED. Of these patients,
up to 15% are admitted to the ED observation ward or a
hospital ward, mainly because the patients are elderly and lack
social support.
Selection of Participants
All patients older than 17 years, with an acute arthritis
suggestive of gout, and presenting to the ED during designated
periods when research staff were on duty between 9 AM and 4
PM, Monday to Friday, from February 1, 2003, to June 30,
2004, were considered for enrollment. Patients were included if
they had a clinical diagnosis of acute arthritis suggestive of gout,
defined as the presence of pain and warmth in a joint, and
presented within 3 days of the onset of pain and also had 1 or
more of the following: metatarsal-phalangeal joint involvement;
knee or ankle joint involvement and aspirate containing crystals;
or typical gouty arthritis, with either gouty tophi present or
previous joint aspiration confirming the diagnosis of gout.
Patients were excluded if there was a clinical suspicion of
sepsis or other joint disease; if follow-up was impossible because
of lack of transport or lack of telephone contact; if there was
significant comorbidity that would interfere with assessment;
and if patients had dementia, confusion, active gastrointestinal
symptoms, renal insufficiency with serum creatinine level
greater than 200 mol/L, bleeding disorder, allergy to a study
drug, or joint aspirate that excluded the diagnosis of gout or
were taking warfarin.
Editor’s Capsule Summary
What is already known on this topic
Acute gouty arthritis is typically treated with nonsteroidal
antiinflammatory agents, though prednisone has also
been recommended. Their relative efficacy is unknown.
What question this study addressed
The efficacy and adverse effects of oral prednisolone and
oral indomethacin in the treatment of acute goutlike
arthritis in emergency department patients.
What this study adds to our knowledge
In this 90-patient randomized controlled trial, the
treatments exhibited similar efficacy. Adverse effects were
more common in patients given indomethacin, including
gastrointestinal bleeding in 11%.
How this might change clinical practice
A short course of prednisolone is at least as effective as
indomethacin and may be safer.
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It is often not possible to definitively separate gout from
septic arthritis on clinical grounds alone. In this study, sepsis
was considered likely if the patient had a temperature greater
than 38°C, chills or rigors, a wound near the affected joint, a
history of immunosuppression, erythematous tracking along a
lymphatic vessel or vein in the affected limb, lymphadenopathy,
or a history of septic arthritis.
Interventions
Patients were allocated with a random-number table
generated from StatView for Windows, version 5.0 (Abacus
Concepts, SAS Institute, Inc., Cary, NC). The random
allocation sequence was implemented with numbered sealed
envelopes, such that the sequence was concealed until
interventions were assigned. A nurse with clinical
responsibilities opened a precoded envelope with details of the
drug and a randomization number. The oral preparations of
indomethacin 25 mg, acetaminophen 500 mg and prednisolone
5 mg, and identical placebos were all prepacked and placed
inside the envelope. Diclofenac was prepared as a solution at 25
mg/mL, and placebo (normal saline solution) as a 1-mL
solution was prepared in the ED. This nurse was not involved in
the administration of analgesia, the assessment of the patient, or
the treatment of adverse effects. The code was only to be broken
if a physician or other nurse with clinical duties was concerned
about severe adverse effects. Both the research nurse with
nonclinical duties and the patient were blinded to the
medication.
In the indomethacin group, each patient initially received
diclofenac (3 mL; 75 mg) intramuscularly, indomethacin 50 mg
orally, acetaminophen 1 g orally, and 6 tablets of prednisolone-
like placebo orally and was observed for 120 minutes. The
Inclusion/Exclusion Criteria 
Randomization
Indomethacin group 
IM diclofenac 75mg 
+
oral indomethacin 50mg 
+
paracetamol 1g 
+
placebo prednisolone 
indomethacin 50mg TID for 2 days & 25mg 
TID for 3 days 
+
paracetamol 1g 4-hourly as required 
+
placebo prednisolone 30mg daily for 5 
days
Telephone review 24 hours or physical 
review if in ‘O’ Ward 
Physical review after 5 days 
Cease indomethacin if signficiant 
improvement 
Further review 14 days 
Indo ethacin group 
I  diclofenac 75 g 
+
oral indo ethacin 50 g 
+
paraceta ol 1g 
+
placebo prednisolone 
indo ethacin 50 g TI  for 2 days  25 g 
TI  for 3 days 
+
paracetamol 1g every 4 hours as required 
+
placebo prednisolone 30 g daily for 5 
days
Telephone revie  24 hours or physical 
review if in Observation Ward 
hysical revie  after 5 days 
ease indo ethacin if signficant 
i prove ent 
Further revie  14 days 
Prednisolone group 
IM placebo (normal saline) 
+
oral prednisolone 30mg 
+
paracetamol 1g 
+
placebo indomethacin 
prednisolone 30 mg daily for 5 days 
+
paracetamol 1g 4-hourly as required 
+
placebo indomethacin 50mg TID for 2 
days & 25mg TID for 3 days 
Telephone review 24 hours or physical 
review if in ‘O’ Ward 
Physical review 5 days 
Cease prednisolone if significant 
improvement 
Further review 14 days 
rednisolone group 
I  placebo (nor al saline) 
+
oral prednisolone 30 g 
+
paraceta ol 1g 
+
placebo indo ethacin 
prednisolone 30 g daily for 5 days 
+
paracetamol 1g every 4 hours as required 
+
placebo indo ethacin 50 g TI  for 2 
days  25 g TI  for 3 days 
Telephone revie  24 hours or physical 
review if in Observation Ward 
Physical review after 5 days 
ease prednisolone if significant 
i prove ent 
Further revie  14 days 
Figure 1. Progress of patients through randomized trial.TID, Three times a day.
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patient was then given a 5-day prescription of indomethacin
(50 mg orally every 8 hours for 2 days, followed by
indomethacin 25 mg every 8 hours for another 3 days), 6 tablets
of prednisolone-like placebo once a day, and acetaminophen 1 g
every 6 hours as required.
In the prednisolone group, each patient initially received an
intramuscular placebo injection (3 mL), prednisolone 30 mg
(6 times 5 mg) orally, acetaminophen 1 g (2 tablets) orally,
and indomethacin-like placebo (2 tablets) orally, and was then
observed for 120 minutes. The patient was then given a 5-day
prescription of indomethacin-like placebo, prednisolone 30 mg
orally once per day, and acetaminophen 1 g every 6 hours as
required. Both acetaminophen and intramuscular injection were
given in accordance with common local practice. Many patients
in Hong Kong believe that symptomatic relief will be faster if
an injection is administered. The physician on duty was free to
give extra doses or alternative analgesic if clinically required,
and this was documented.
Methods of Measurement
Assessment included demographic data, assessment on
scheduled intervals of pain scores at rest and with activity, the
occurrence of adverse effects, and the time of symptom
resolution. The pain scores were assessed with a visual analogue
scale from 0 (absence of pain) to 10 (the most severe pain the
patient has ever experienced). A 10-cm, numbered, horizontal,
visual analogue pain score was used for baseline measurements
(t0) and at subsequent intervals after the first injection.
20 Pain
scores and adverse effects were recorded every 30 minutes for 2
hours after drug administration. Patients were aware of their
previous scores at all stages of recording.
Research staff contacted the patient by telephone at 24 hours
(or physical assessment if the patient was admitted to the
observation ward), at 5 days, and also by telephone at 14 days,
unless symptoms were not resolved. Patients recorded data daily
for 5 days at home.
The type, number, duration, and severity of adverse effects
were documented. Specific questions for each adverse event
were asked each day in the collection of adverse event data,
eg, “Did you experience nausea today?”
The primary clinical outcome measures were pain relief,
measured as changes in pain score at rest and with activity, and
adverse events. Both the change in the score and absolute value
were measured. Activity involved the research nurse gently
moving the joint involved in a standardized manner to assess
pain. Adverse events were assessed for number, duration, and
severity (where applicable). Secondary outcome measures were
time to complete resolution of pain, stiffness and joint swelling,
supplementary acetaminophen, and relapse rate. Data collection
ceased at day 14, and nonresolution of symptoms or recurrence
of symptoms at this time was regarded as a treatment failure.
Primary Data Analysis
Data were analyzed on an intention-to-treat basis, and all
statistical analyses involved 2-tailed tests using StatView for
Windows, version 5.0 Statistical Analysis Software (Abacus
Concepts, SAS Institute). P.05 was considered as statistically
significant. Because pain score and time data did not conform to
the Gaussian distribution, nonparametric tests were used to
analyze data.21 Baseline characteristics of the 2 treatments were
analyzed using the 2 test or Mann-Whitney U test.22 A
regression line indicating the change in visual analog scale pain
score over time was found, and its slope was therefore a
summary measure for each patient.23 The distribution of
coefficients followed a normal distribution, and so the mean
slope for the coefficients of each treatment group was compared
and analyzed using the t test. A previous study has shown that a
difference in visual analog pain scores of less than 13 mm is
unlikely to be clinically relevant.24 Therefore, unless the upper
limits of the confidence intervals (CIs) were less than 13 mm,
we assumed that the results were inconclusive.
To detect a clinically significant difference between the mean
pain score of the 2 groups of 15 mm, each with an SD of 20
mm, with an estimated power of 90% and at the 5%
significance level, 37 patients were required for each group.
RESULTS
During the study period, 112 patients presented with a
clinical diagnosis of probable acute gout, of whom 22 were
excluded because of acute gastroduodenal ulcer (n1), trauma
(n3), serum creatinine level greater than 200 nmol/L (n3),
bleeding disorders (n3), history of adverse reactions to
NSAID (n5), and suspicion of infectious cause (n6). The
remaining 90 patients were randomized, 46 patients to the
indomethacin group and 44 patients to the prednisolone group
(Figure 2).
The demographic and other baseline characteristics of the
2 groups were similar (Table 1). There was no significant
difference in initial mean pain score at rest or with activity
between the 2 treatment groups. Five patients in the
prednisolone group and 2 patients in the indomethacin group
agreed to allow joint aspiration. All were positive for urate
crystals and negative for bacterial culture.
During the ED phase, the rate of decrease in mean pain score
over time both at rest and with activity (Figure 3) was similar
for both groups. The mean rate of decrease in pain score at rest
for indomethacin was 6.48.3 (SD) mm per hour and for
prednisolone was 9.510.5 (SD) mm per hour (mean
difference 3.2 mm/hour; 95% CI 0.78 to 7.14 mm/hour;
P.12). The mean rate of decrease in pain score with activity
for indomethacin was 20.39.1 (SD) mm per hour and for
prednisolone was 19.211.2 (SD) mm per hour (mean
difference 1.0 mm/hour; 95% CI 5.34 to 3.24 mm/hour;
P.63).
During the follow-up phase, the rate of decrease in mean
pain score over time at rest and with activity (Figure 4) was
greater in the prednisolone group than the indomethacin group.
The mean rate of decrease in pain score at rest for indomethacin
was 0.30.7 (SD) mm per day and for prednisolone was
0.71.2 (SD) mm per day (mean difference 0.5 mm/day;
Man et al Treatments for Acute Goutlike Arthritis
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95% CI 0.03 to 0.89 mm/day; P.04). The mean rate of
decrease in pain score with activity for indomethacin was
1.71.6 (SD) mm per day and for prednisolone was
2.92.0 (SD) mm per day (mean difference 1.2 mm/day;
95% CI 0.44 to 2.00 mm/day; P.0026). Although these
differences in activity were statistically significant, at no time
was the difference in mean pain score greater than 13 mm.
At day 14 (the last follow-up day), the same end points were
reached by the 2 groups.
Both treatment groups showed improvement in the joint
swelling and stiffness, but there was no difference in
improvement between the 2 groups.
In the indomethacin group, 29 (63%) patients experienced
adverse effects compared with 12 (27%) patients in the
prednisolone group (P.05; Table 2). Nausea, indigestion,
epigastric pain, and dizziness were significantly more common
in the indomethacin group than the prednisolone group. The
most common adverse effects in the steroid group were dry
mouth and dizziness.
Seven patients had adverse effects that were serious enough
to require treatment or hospital admission; all were in the
indomethacin group (P.007). Five (11%) patients developed
gastrointestinal bleeding (11%; P.05). Their ages ranged from
62 to 84 years. Four were admitted to the hospital, and the fifth
was referred to an outpatient clinic. In each case, study
medication was stopped, and upper gastrointestinal endoscopy
was performed; 3 patients had acute gastric ulcers, of whom 2
received adrenaline injection for active bleeding; 2 patients had
gastroduodenal ulcers. No patient developed cardiovascular
shock, and all ulcers healed after treatment.
All patients in the 2 groups consumed acetaminophen during
the 14 days. The mean total dose of acetaminophen consumed
by the prednisolone group was significantly more than that
consumed by the indomethacin group (mean 10.3 g, range 1 to
21 g versus mean 6.4 g, range 1 to 21 g; P.008). Overall,
within 14 days there were 8 patients in the indomethacin group
who relapsed and reattended for further treatment compared
with 5 patients in the prednisolone group (Pnonsignificant).
Fifteen patients in the prednisolone group required alternative
medication for pain relief compared with 17 patients in the
indomethacin group (Pnonsignificant).
LIMITATIONS
The diagnosis was made on clinical impression, and joint
aspiration was not performed on most patients. However, in
routine clinical practice the majority of patients presenting with
goutlike arthritis are treated clinically and without joint
aspiration, unless there is a high index of suspicion of septic
arthritis or atypical features. The relatively small sample size
may not have allowed us to detect small differences in pain
scores. The sample size was based on our estimation of a
clinically significant difference. The safety aspects were not a
primary aspect of the study, and as such it was not powered to
evaluate safety. It is possible that with larger numbers of
Table 1. Baseline characteristics of patients between the
2 groups.
Variable
Indomethacin
Group, N46
Prednisolone
Group,
N44
Age, y, mean (SD) 66 (16) 64 (15)
Male patients (%) 39 (85) 35 (80)
History of gout, No. (%) 45 (98) 42 (95)
Duration of symptoms, d, mean (SD) 2.3 (0.6) 2.2 (1.1)
Pain score at rest (pretreatment), mm,
mean (SD)
15 (20.8) 24 (25.2)
Pain score with activity (pretreatment),
mm, mean (SD)
74 (20.3) 78 (19.7)
Single joint involved, patients (%) 45 (98) 41 (93)
1 Joint involved, No. (%) 1 (2) 3 (7)
Lower limb involved, No. (%) 45 (98) 39 (89)
Lower and upper limb involved, No. (%) 1 (2) 0
Fever, No. (%) 8 (17) 2 (5)
Presence of tophus, No. (%) 2 (4) 5 (11)
Mobility, unable to bear weight, No. (%) 25 (54) 29 (66)
Admission to observation ward, No. (%) 3 (7) 8 (18)
Median length of stay in observation
ward, h
23.6 23.4
Assessed for eligibility 
(n=112) 
Excluded (n=22) 
Randomised (n=90) 
Allocated to indomethacin 
(n=46) 
All received allocated 
intervention (n=46) 
Allocated to prednisolone 
(n=44) 
All received allocated 
intervention (n=44) 
Able to follow-up (n=46) 
Lost to follow-up (n=0)  
Analysed (n=46) 
Able to follow-up (n=44) 
Lost to follow-up (n=0) 
Analysed (n=44) 
Figure 2. Interventions given to patients randomized into
the 2 study groups.
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patients, the prednisolone group would also have had some
significant adverse events. Finally, the use of placebo injections
is artificial and not standard practice. The use of placebo was
important to ensure complete blinding but introduces the
problem of artificiality. To what extent this limits application to
clinical practice is not clear.
DISCUSSION
This is the first double-blind randomized placebo-controlled
study comparing commonly used, inexpensive, and easily available
indomethacin and prednisolone in the treatment of acute goutlike
arthritis. Our results indicate that the treatment of acute goutlike
arthritis with commonly prescribed doses and frequencies of
prednisolone and indomethacin produces similar pain relief.
However, patients in the prednisolone group took significantly
more acetaminophen than the indomethacin group as an adjunct
for pain relief. Prednisolone supplemented with acetaminophen
may be as effective as indomethacin in relieving pain. Patients
taking prednisolone experienced far fewer serious or other adverse
effects compared with patients taking indomethacin.
Although NSAIDs have been recommended as the first-line
therapy for acute gouty arthritis,25 there have been some studies
on the role of steroid in the treatment of the condition. In a
small preliminary study, it was suggested that a short course of
oral corticosteroid therapy could be used effectively for acute
gout when NSAIDs are contraindicated.16 Subsequently, in
another small study of 27 patients, single intramuscular
injections of betamethasone, intravenous methylprednisolone,
or oral diclofenac resulted in prompt and equal improvement.26
Glucocorticoid therapy was well tolerated. The sample size was
small, adverse effects were not reported, and oral corticosteroids
were not used. In another small study (27 patients), the safety
and effectiveness of intramuscular triamcinolone in the
treatment of acute gout were also noted.27
-20
0
20
40
60
80
100
V
is
u
a
l A
n
a
lo
g
u
e
 P
a
in
 S
c
o
re
P
S
A
R
 T
0
P
S
A
R
 T
3
0
P
S
A
R
 T
6
0
P
S
A
R
 T
9
0
P
S
A
R
 T
1
2
0
Prednisolone
Indomethacin
0
20
40
60
80
100
V
is
u
a
l A
n
a
lo
g
u
e
 P
a
in
 S
c
o
re
P
S
A
A
 T
0
P
S
A
A
 T
3
0
P
S
A
A
 T
6
0
P
S
A
A
 T
9
0
P
S
A
A
 T
1
2
0
Prednisolone
Indomethacin
At rest With activity 
Figure 3. Visual analog pain score at rest and with activity during the ED phase. Pain was assessed at rest, at time (T) 0,
and at 30 min, 60 min, 90 min, and 120 min. Data are presented as means (95% CIs). There were no statistically or
clinically significant differences between the groups either at rest (P.12) or with activity (P.63).
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Figure 4. Visual analog pain score at rest and with activity during the follow-up phase. Pain was assessed at rest for days
(D) 1 to 5 and 14. Data are presented as means (95% CIs). There were no statistically or clinically significant differences
between the groups at any point either at rest (P.60) or with activity (P.0026) (see text).
Table 2. Adverse effects reported by patients treated with
indomethacin or prednisolone for the acute goutlike arthritis.*
Adverse Effects
Indomethacin
(N46)
Prednisolone
(N44) P Value
Any adverse event, No. (%) 29 (63) 12 (27) .0007
Epigastric pain, of No. (%) 14 (30) 0 (0) .0001
Other abdominal pain, No. (%) 3 (7) 0 (0) .09
Rash, No. (%) 1 (2) 3 (7) .25
Dizziness, No. (%) 9 (19) 2 (5) .03
Drowsiness, No. (%) 9 (19) 7 (16) .79
Dry mouth, No. (%) 11 (24) 9 (20) .83
Indigestion, No. (%) 14 (30) 4 (9) .02
Nausea, No. (%) 12 (26) 3 (9) .02
Vomiting, No. (%) 4 (9) 0 .05
Diarrhea, No. (%) 3 (7) 0 .09
Serious adverse effects
requiring admission,
No. (%)
7 (15) 0 .007
Gastrointestinal hemorrhage,
No. (%)
5 (11) 0 .05
Shortness of breath, No. (%) 1 (2) 0 .98
Chest pain, No. (%) 1 (2) 0 .98
*Percentages may not sum to 100, because of rounding.
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A review article by Kim et al1 reported that therapies
available for managing acute gout, which included
corticotropin, corticosteroids, colchicines, and NSAIDs, were
associated with significant adverse events. However, in our
study, we found that there were no cases of upper
gastrointestinal bleeding in the group treated with prednisolone,
whereas 5 (11%) patients in the indomethacin group developed
upper gastrointestinal bleeding. Although none of the patients
died because of the adverse effects, the occurrence of upper
gastrointestinal bleeding, especially in the elderly, is a cause of
significant morbidity.9-12
The pain score at rest and during activity followed a similar
pattern and trend of improvement in both the prednisolone and
indomethacin groups. However, patients in the prednisolone
group used slightly more acetaminophen, suggesting that
prednisolone alone may not be enough to relieve the pain
associated with the disease. Studies that compared
cyclooxygenase-2 (COX-2) inhibitors with NSAIDs found that
the former had a similar comparable efficacy but better
tolerability.28-30 However, COX-2 inhibitors are expensive and
are less accessible to the general population. Even more
important is the concern about the cardiovascular safety of
COX-2 inhibitors.28,31,32 The use of corticosteroids in the
treatment of acute gout has also been known to be effective.
Corticosteroids have been used clinically in the treatment of a
large variety of conditions, ranging from allergic or ectopic
diseases, asthma, and connective tissue diseases to other
inflammatory conditions.
Analgesic recommendations usually rank corticosteroids as a
second line of treatment, whereas the NSAIDs are usually tried
first.4,25 There are several possible reasons for physicians’
reluctance to use corticosteroids. Physicians have more
experience with NSAIDs in the treatment of gout. In addition,
corticosteroids have received bad publicity in terms of their
numerous long-term adverse effects such as Cushing syndrome,
osteoporosis, diabetes mellitus, and hypertension. The recent
report of avascular necrosis after use of high-dose
methylprednisolone in the treatment severe acute respiratory
syndrome is another vivid example.33
Our results are in line with epidemiologic reports that acute
gouty arthritis most commonly affects elderly patients and that
the risk of serious gastrointestinal toxicity of NSAIDs is higher
in this age group.8 According to the findings in our study, we
recommend that moderate doses of oral prednisolone
supplemented with oral acetaminophen be considered as
first-line therapy in the treatment of acute gout.
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